Dr. Molineaux is a co-founder of Calithera Biosciences and has served as the company’s Chief Executive Officer since the company’s founding in June 2010. Dr. Molineaux was most recently a founder, CSO and CEO of Proteolix, a company that discovered and developed proteasome inhibitors for the treatment of cancer and autoimmune disease. Prior to joining Proteolix, Dr. Molineaux was Vice President, Biology at Rigel Pharmaceuticals from 2000 to 2003. Before that, she was Vice President, Biology at Praelux, and from 1994 through 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals. From 1989 until 1994 she was a scientist in the Immunology group at Merck, in Rahway, NJ. Dr. Molineaux received a B.S. degree in Biology from Smith College, a Ph.D. degree in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.